Andre Goy, MD, MS

Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is shaping the future of cancer treatment, with key insights from the JTCC highlighting emerging therapies and their potential to improve patient outcomes through personalized approaches.

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.